CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 187 enrolled
Drug / intervention
Azacitidinedrug
Likely dose
Azacitidine 32 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00887068
NCT00887068Phase 3Completed
CompareCT.gov

Randomized Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)

M.D. Anderson Cancer Center·interventional·Posted Apr 23, 2009·Updated Jan 14, 2020

In Brief

A Phase 3 clinical trial evaluating Azacitidine for Leukemia and 2 related conditions. Completed, enrolled 187 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if Vidaza (azacitidine) will help to control the disease in patients with AML, CMML, or MDS after an allogeneic (donor) stem cell transplant. The safety of this drug will also be studied.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia, AML, MDS
CountriesUnited States
CollaboratorsCelgene

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 23, 2009
Enrollment StartApr 21, 2009
Primary CompletionAug 20, 2018
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 17.2 years ago

Interventions

Azacitidinedrug

32 mg/m\^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.